Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

CeQur acquires wearable insulin delivery device

July 17, 2018 By Sarah Faulkner Leave a Comment

CeQur Calibra insulin delivery deviceCeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount.

The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction scores, as well as less glycemic variability compared to insulin injection pens.

Marlborough, Mass.-based CeQur plans to launch Calibra’s insulin delivery device under a new name next year, the company said.

“CeQur is dedicated to simplifying insulin dosing for people with diabetes, so that they can live healthier, more satisfying lives,” CEO Robert Farra said in prepared remarks. “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery. The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.”

“This device will enable us to begin reaching the diabetes community with simple, discreet, three-day insulin delivery that will free people from having to inject multiple times per day,” Farra added.

“The Calibra device is well designed with impressive clinical results,” CeQur’s executive chairman, Eric Milledge, said. “The number of people with diabetes who require insulin will continue to grow. Given the proven benefits of this device, as well as the range of patients it can support, CeQur will improve the health and simplify the lives of these individuals.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: cequr, johnsonandjohnson

IN CASE YOU MISSED IT

  • When human factor specialists become the patient
  • Phillips-Medisize is expanding in Wisconsin
  • Cash-strapped Aradigm declares bankruptcy
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS